Breast cancer proteomics: A review for clinicians

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 6, 2011, Pages 915-925

  Galvao E R C G N ^a,b   Martins, L M S ^a   Ibiapina, J O ^a,b   Andrade, H M ^c   Monte, S J H ^d  

^a UNIVERSIDADE ESTADUAL DO PIAUÍ   (Brazil)

^b HOSPITAL DE BRAGA   (Portugal)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

Author keywords

2D DIGE; Breast neoplasms; MALDI TOF MS; Mass spectrometry; Proteomics

Indexed keywords

BETA CRYSTALLIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CALCYCLIN; CALGRANULIN A; CATH PROTEIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FERRITIN; HEAT SHOCK PROTEIN 27; HER3 PROTEIN; LIPOCORTIN 5; LIPOPROTEIN; MASPIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN 14 3 3; PROTEOME; RAF PROTEIN; SOMATOMEDIN C RECEPTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BREAST CANCER; CANCER DIAGNOSIS; CANCER TISSUE; CLINICAL PRACTICE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATIENT CARE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; STATISTICAL ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BREAST NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; NEOPLASM PROTEINS; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79959722021     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-0978-0     Document Type: Review

References (83)

1. Abramovitz M, Leyland-Jones B (2006) A systems approach to clinical oncology: focus on breast cancer. Proteome Sci 4:5
2. Aggarwal K, Choe LH, Lee KH (2006) Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 5:112-120 (Pubitemid 46403004)
3. Andersson T, Johansson M, Bolmsjo G, James P (2007) Automating MALDI sample plate loading. J Proteome Res 6:894-896 (Pubitemid 46340194)
4. Barazi HO, Zhou L, Templeton NS, Krutzsch HC, Roberts DD (2002) Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res 62:1541-1548 (Pubitemid 34407820)
5. Bergman AC, Benjamin T, Alaiya A et al (2000) Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21:679-686 (Pubitemid 30118238)
6. Bertucci F, Goncalves A (2008) Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. Future Oncol 4:271-287 (Pubitemid 351715784)
7. Bertucci F, Birnbaum D, Goncalves A (2006) Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5:1772-1786 (Pubitemid 44688187)
8. Bouchal P, Roumeliotis T, Hrstka R, Nenutil R, Vojtesek B, Garbis SD (2009) Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 8:362-373
9. Brozkova K, Budinska E, Bouchal P et al (2008) Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 10:R48
10. Callesen AK, Vach W, Jorgensen PE et al (2008) Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J Proteome Res 7:1395-1402
11. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86-103 (Pubitemid 40942470)
12. Cornett DS, Mobley JA, Dias EC et al (2006) A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics 5:1975-1983 (Pubitemid 44688205)
13. Cowherd SM, Espina VA, Petricoin EF III, Liotta LA (2004) Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer 5:385-392 (Pubitemid 40109647)
14. Dean RA, Overall CM (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 6:611-623 (Pubitemid 46630094)
15. Domon B, Aebersold R (2006) Mass spectrometry and protein analysis. Science 312:212-217
16. Ferguson AT, Evron E, Umbricht CB et al (2000) High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97:6049-6054 (Pubitemid 30367521)
17. Fu H, Subramanian RR, Masters SC (2000) 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617-647 (Pubitemid 30340695)
18. Gast MC, Schellens JH, Beijnen JH (2009) Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 116:17-29
19. Gilabert M, Audebert S, Viens P, Borg JP, Bertucci F, Goncalves A (2010) Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers. Bull Cancer 97:321-339
20. Giometti CS, Tollaksen SL, Chubb C, Williams C, Huberman E (1995) Analysis of proteins from human breast epithelial cells using two-dimensional gel electrophoresis. Electrophoresis 16:1215-1224
21. Goncalves A, Charafe-Jauffret E, Bertucci F et al (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420-1433
22. Haab BB (2005) Antibody arrays in cancer research. Mol Cell Proteomics 4:377-383
23. Habermann JK, Roblick UJ, Luke BT et al (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131:1020-1029; quiz 284
24. Hondermarck H (2003) Breast cancer: when proteomics challenges biological complexity. Mol Cell Proteomics 2:281-291
25. Hondermarck H, Vercoutter-Edouart AS, Revillion F et al (2001) Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1:1216-1232
26. Hondermarck H, Tastet C, Yazidi-Belkoura El et al (2008) Proteomics of brest cancer: the quest for markers and therapeutic targets. J Proteome Res 7:1403-1411
27. Hudelist G, Singer CF, Pischinger KI et al (2006) Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 6:1989-2002
28. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277-300
29. Kabbage M, Chahed K, Hamrita B et al (2008) Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol 2008:564127
30. Kamradt MC, Chen F, Cryns VL (2001) The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276:16059-16063
31. Kamradt MC, Lu M, Werner ME et al (2005) The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280:11059-11066 (Pubitemid 40418409)
32. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646 (Pubitemid 37310920)
33. Leong S, Christopherson RI, Baxter RC (2007) Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol Biochem 20:579-590 (Pubitemid 47340618)
34. Li DQ, Wang L, Fei F, Hou YF et al (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6:3352-3368 (Pubitemid 43886152)
35. Liu Y, Liu H, Han B, Zhang JT (2006) Identification of 14-3-3sigma as contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66:3248-3255
36. Martini PG, Delage-Mourroux R, Kraichely DM et al (2000) Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol Cell Biol 20:6224-6232 (Pubitemid 30650209)
37. Mian S, Ball G, Hombuckle J et al (2003) A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 3:1725-1737 (Pubitemid 37129820)
38. Miller I, Crawford J, Gianazza E (2006) Protein stains for proteomic applications: which, when, why? Proteomics 6:5385-5408
39. Mitrunen K, Hirvonen A (2003) Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 544:9-41
40. Moreira JM, Ohlsson G, Rank FE, Celis JE (2005) Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4:555-569 (Pubitemid 40590572)
41. Moyano JV, Evans JR, Chen F et al (2006) Alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116:261-270 (Pubitemid 43121811)
42. Nakagawa T, Huang SK, Martinez SR et al (2006) Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 66:11825-11830 (Pubitemid 46094194)
43. Nesvizhskii AI (2007) Protein identification by tandem mass spectrometry and sequence database searching. Methods Mol Biol 367:87-119
44. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK (2003) Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA 100:9330-9335 (Pubitemid 37033928)
45. Page MJ, Amess B, Townsend RR et al (1999) Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 96:12589-12594 (Pubitemid 29513546)
46. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167
47. Patton WF (2002) Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 771:3-31
48. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26:1-10
49. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
50. Pucci-Minafra I, Cancemi P, Marabeti MR et al (2007) Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts. Proteomics Clin Appl 1:118-129
51. Reis-Filho JS, Lakhani SR (2003) The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 5:313-319
52. Reis-Filho JS, Lakhani SR (2008) Breast cancer special types: why bother? J Pathol 216:394-398
53. Reis-Filho JS, Tutt NA (2008) Triple negative tumours: a critical review. Histopathology 52:108-118 (Pubitemid 350265179)
54. Ricolleau G, Charbonnel C, Lode L et al (2006) Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6:1963-1975
55. Rodenhiser D, Mann M (2006) Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 174:341-348 (Pubitemid 43235307)
56. Sanders ME, Dias EC, Xu BJ et al (2008) Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J Proteome Res 7:1500-1507
57. Schulz DM, Bollner C, Thomas G et al (2009) Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 8:3430-3438
58. Sethuraman M, Clavreul N, Huang H, McComb ME, Costello CE, Cohen RA (2007) Quantification of oxidative posttranslational modifications of cysteine thiols of p21ras associated with redox modulation of activity using isotope-coded affinity tags and mass spectrometry. Free Radic Biol Med 42:823-829 (Pubitemid 46274168)
59. Simpson RJ, Bernhard OK, Greening DW, Moritz RL (2008) Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol 12:72-77
60. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
61. Stastny J, Prasad R, Fosslien E (1984) Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis. Clin Chem 30:1914-1918 (Pubitemid 15079377)
62. Sutton CW, Rustogi N, Gurkan C et al (2010) Quantitative proteomic profiling of matched normal and tumor breast tissues. J Proteome Res 9:3891-3902
63. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, Sager R (1990) Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA 87:2319-2323
64. Traub F, Feist H, Kreipe HH, Pich A (2005) SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol Res Pract 201:763-770 (Pubitemid 43071563)
65. Traub F, Jost M, Hess R et al (2006) Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest 86:246-253 (Pubitemid 43276956)
66. Tsitsilonis OE, Bekris E, Voutsas IF et al (1998) The prognostic value of alpha-thymosins in breast cancer. Anticancer Res 18:1501-1508 (Pubitemid 28342551)
67. Umar A, Dalebout JC, Timmermans AM, Foekens JA, Luider TM (2005) Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics 5:2680-2688 (Pubitemid 40966495)
68. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S (2001) Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20:3348-3353 (Pubitemid 32588983)
69. van't Veer LJ, Dai H, van de Vijver MJ et al (2003) Expression profiling predicts outcome in breast cancer. Breast Cancer Res 5:57-58
70. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X et al (2001) Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61:76-80 (Pubitemid 32095703)
71. Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220:263-280
72. Weiss JM, Goode EL, Ladiges WC, Ulrich CM (2005) Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 42:127-141 (Pubitemid 40271142)
73. Wilkins MR, Sanchez JC, Gooley AA et al (1996) Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13:19-50
74. Wirth PJ (1989) Specific polypeptide differences in normal versus malignant breast tissue by two-dimensional electrophoresis. Electrophoresis 10:543-554
75. Worland PJ, Bronzert D, Dickson RB et al (1989) Secreted and cellular polypeptide patterns of MCF-7 human breast cancer cells following either estrogen stimulation or v-H-ras transfection. Cancer Res 49:51-57 (Pubitemid 19024406)
76. Wright GL Jr (1974) Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann Clin Lab Sci 4:281-293
77. Wulfkuhle JD, McLean KC, Paweletz CP et al (2001) New approaches to proteomic analysis of breast cancer. Proteomics 1:1205-1215
78. Yiu CC, Sasano H, Ono K, Chow LW (2010a) Changes in protein expressions after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance. Expert Opin Investig Drugs 19(Suppl 1):S79-S89
79. Yiu CC, Chanplakorn N, Chan MS et al (2010b) Down regulation of Heat Shock Protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor (AI) therapy in breast cancer patients. Anticancer Res 30:3465-3472
80. Zeidan BA, Cutress RI, Murray N et al (2009) Proteomic analysis of archival breast cancer serum. Cancer Genomics Proteomics 6:141-147
81. Zhang F, Chen JY (2010) Discovery of pathway biomarkers from coupled proteomics and systems biology methods. BMC Genomics 11(Suppl 2):512
82. Zhang Z, Bast RC Jr, Yu Y et al (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890 (Pubitemid 39095590)
83. Zhang Y, Newcomb PA, Egan KM et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353-358 (Pubitemid 43342187)